Last mentioned: Feb 25, 2026
Institutional Exit Revealed
13F filings reveal a $170 million divestment by a major institutional fund.
120% Gain Milestone
PTGX stock reaches a 120% gain milestone from its 52-week low.
J&J Partnership Milestone
Johnson & Johnson advances JNJ-2113 into late-stage trials, validating oral peptide tech.
Phase 3 Data Release
Positive Phase 3 data for rusfertide in polycythemia vera triggers initial stock rally.
Protagonist Therapeutics shares have soared 120% following clinical and regulatory milestones, but a recent $170 million institutional exit is raising questions about the stock's near-term ceiling. The move highlights a growing divergence between retail momentum and institutional profit-taking in the biotech sector.
This page surfaces every story mentioning JNJ-2113 across our finance coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running finance beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where JNJ-2113 was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |